Not available
Quote | Redhill Biopharma Ltd. (NASDAQ:RDHL)
Last: | $0.452 |
---|---|
Change Percent: | 0.19% |
Open: | $0.42 |
Close: | $0.452 |
High: | $0.455 |
Low: | $0.401 |
Volume: | 329,184 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Redhill Biopharma Ltd. (NASDAQ:RDHL)
2024-04-08 14:07:22 ET More on RedHill RedHill Biopharma looks to raise $1.25M in a direct offering of securities RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042 Financial information for RedHill Read the full article o...
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base ...
Message Board Posts | Redhill Biopharma Ltd. (NASDAQ:RDHL)
Subject | By | Source | When |
---|---|---|---|
RedHill's RHB-102 (BEKINDA) and Opaganib Granted New Patents | midastouch017 | investorshub | 05/01/2023 12:05:58 PM |
JOHANNESBURG, April 28, 2023 /PRNewswire/ --(NASDAQ: $RDHL) ("RedHill" | midastouch017 | investorshub | 04/28/2023 4:37:20 PM |
Whatever happened to the crohns disease drug? They | seve333 | investorshub | 04/28/2023 3:18:25 PM |
Discussions for potential commercialization partners are ongoing. | midastouch017 | investorshub | 04/28/2023 12:33:27 PM |
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results | midastouch017 | investorshub | 04/28/2023 12:26:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights PR Newswire RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base ...
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , April 2, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialt...
RedHill Announces New USPTO Patent Covering Talicia® Through 2034 PR Newswire U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia 1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until Feb...